Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Venture capitalists are looking to put their money into med-tech’s next disruptive device maker, not the companies that follow on its heels.
An FDA advisory panel recommends approval for Dune Medical’s MarginProbe breast cancer detection device.
Biomet tells the SEC that a distributor in the Middle East broke their agreement with sales of dental products to Iran.
A federal judge tossed a lawsuit filed in 2010 accusing Medtronic of violating patents held by W.L. Gore & Associates covering stent graft manufacturing techniques.
Teleflex agreed to pay $30 million in cash and possibly another $50 million in milestone payments for Semprus BioSciences, according to sources familiar with the deal who are not authorized to speak on the record.
Stentys looks to prove its latest Apposition IV self-apposing drug-eluting stent by going head-to-head against Medtronic’s Resolute DES in heart attack patients.
The FDA probes Fresenius Medical after more than 900 patients experienced heart attacks at the company’s internal dialysis centers, as detailed in a company memo that wasn’t shared with other Fresenius dialysis device users.